Method for detecting high-sensitivity tumor residues in TIL product and application of method

By using qPCR amplification method and specific primers to quantitatively analyze the CK7 gene in TIL products, the problem of insufficient sensitivity for tumor cell residue detection in the prior art was solved, and high-sensitivity lung cancer cell residue detection was achieved, with the lower detection limit reaching ten Five out of ten thousand ensures the accuracy and safety of the detection.

CN119082303APending Publication Date: 2024-12-06NINGBO XINUOSAI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411262699.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing tumor cell residue detection methods are difficult to meet the actual requirements in terms of sensitivity and accuracy, especially in TIL products, where there are difficulties in selecting detection genes for different types of tumors, resulting in complex detection and large interference from human factors.

Method used

Using qPCR amplification method combined with specific primers, through quantitative analysis of CK7 gene, the specific primer sequence was designed as forward primers: 5'-TCCGCGAGGTCACCATTAAC-3' and reverse primers: 5'-GCTCTGTCAACTCCGTCTCAT-3' to achieve lung cancer The detection limit for high sensitivity of cells remains reaches 5/100,000.

Benefits of technology

It improves the sensitivity of tumor cell residue detection, realizes low-cost, high-sensitivity, extremely low-proportion non-small cell lung cancer residual detection, ensures the safety of TIL products, and significantly improves the accuracy and repetition of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082303A_ABST
    Figure CN119082303A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting high-sensitivity tumor cell residues in a TIL product and application of the method, the detection method is used for detecting the tumor cell residues in tumor infiltration lymphocytes, specific primers are adopted in the detection process, and the sequences of the specific primers are shown as follows: a forward primer is 5 '-TCCGCGAGGTCACCATAAC-3', and a reverse primer is 5 '-GCTCTGTCAACTCGTCTCAT-3'; according to the method, the detection sensitivity of the tumor cell residues can be improved, and the lower detection limit of the detection method reaches five hundred thousand.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of residual lung cancer cell content detection, and specifically to a high-sensitivity (lower limit of detection can reach 0.5 parts per 100,000) tumor cell residual detection method in a TIL (tumor infiltrating lymphocyte) product and its application. Background Art

[0002] As an emerging treatment method for solid tumors, tumor infiltrating lymphocyte (TIL) therapy has shown significant advantages in the field of solid tumor treatment. TIL isolated from in situ solid tumors or metastatic lesions are activated, amplified and optimized in vitro and then infused back into patients to achieve safe and effective clinical efficacy. In addition to ensuring the full amplification (quantity) and immunological activity (quality) of lymphocytes, the TIL process also needs to solve the problem of tumor cell residues; although tumor cells gradually apoptosis due to the relative lack of nutrients and the continuous attack of lymphocytes during TIL culture, the possibility of tumor cell residues cannot be completely ruled out in theory. Currently, the commonly used methods for detecting tumor cell residues include: flow cytometry, immunohistochemistry, in situ hybridization and polymerase chain reaction to detect tumor-associated antigens (TAA). Compared with the first three methods, the significant advantages of polymerase chain reaction (PCR) detection technology are high sensitivity and good specificity. The key to PCR detection of tumor cell residues lies in the selection of TAA and the design of primers.

[0003] CK7 protein cytokeratin 7 (CK7), an epithelial marker, is usually expressed in adenocarcinoma, glandular epithelial and transitional epithelial cells, and non-epithelial cells. The residual tumor in TIL products is detected by detecting the expression of CK7 mRNA. The TC cell line is used as a standard to construct a standard curve, and the CK7 gene is quantitatively analyzed to determine the residual tumor in the TIL test product.

[0004] Commonly used methods for detecting residual tumor cells include: flow cytometry, immunohistochemistry, in situ hybridization, and PCR technology; flow cytometry, immunohistochemistry, and in situ hybridization can all show the residual tumor cells in a relatively intuitive form, but due to the limitations of the methods themselves, the sensitivity and accuracy of the detection do not meet the actual requirements, and the experimental process is relatively complex and is subject to greater interference from human factors. Using PCR technology to detect residual tumor cells can greatly improve the sensitivity of residual tumor cell detection, but the selection of detection genes for different types of tumors is the key and difficulty of the experiment. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present application provides a high-sensitivity tumor residual detection method in a TIL product that can improve the sensitivity of tumor cell residual detection.

[0006] In order to solve the above technical problems, the technical solution adopted in the present application is: a high-sensitivity tumor residual detection method in TIL products, which is used to detect the residual amount of tumor cells in tumor infiltrating lymphocytes.

[0007] Furthermore, the detection method is used to detect the residual amount of lung cancer tumor cells in tumor infiltrating lymphocytes.

[0008] Furthermore, the detection method adopts qPCR amplification method.

[0009] Furthermore, specific primers are used in the reaction system of the qPCR amplification method, and the sequences of the specific primers are as follows:

[0010] Forward primer: 5'-TCCGCGAGGTCACCATTAAC-3',

[0011] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′.

[0012] Furthermore, the specific primers are used to amplify the CK7 gene.

[0013] Furthermore, the detection limit of the high-sensitivity tumor residual detection method in the above-mentioned TIL product reaches 5 parts per 100,000.

[0014] Furthermore, in the qPCR amplification reaction system, the concentration of the forward primer is 10 μM, and the concentration of the reverse primer is 10 μM.

[0015] Furthermore, the detection process of this method also uses quality control samples, and the quality control samples are prepared by mixing PBMC cells and TC cells to prepare the lower limit sample of quantitative analysis: 5 / 100,000 tumor cells; the upper limit sample of quantitative analysis: 100% tumor cells; high concentration quality control sample: 25% tumor cells; medium concentration quality control sample: 2.5% tumor cells; low concentration quality control sample: 0.25% tumor cells.

[0016] Furthermore, the qPCR amplification method is as follows:

[0017] Sample source: TC cDNA, TIL cDNA;

[0018] Primer sequences:

[0019] Forward primer: 5'-TCCGCGAGGTCACCATTAAC-3',

[0020] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0021] qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version;

[0022] The reaction system for qPCR is:

[0023]

[0024] The qPCR reaction procedure is:

[0025]

[0026] The present application also provides an application of a high-sensitivity tumor residual detection method in a TIL product in a kit, the kit comprising reagents: 2x SuperReal PreMix Plus, Forward Primer (10μM), Reverse Primer (10μM), 50×ROX Reference Dye, RNase-free ddH2O.

[0027] Advantages and beneficial effects of this application:

[0028] 1. Through reasonable screening and verification, the technical solution of this application found that CK7 protein is expressed in almost all lung adenocarcinoma cells but not in immune cells, which is a very ideal TAA. The specific amplification of the CK7 gene in vitro was achieved by rationally designing primers. The reverse transcription quantitative PCR method was used to perform linear regression curve analysis with the inverse of the logarithm of the tumor cell (TC) ratio [-log(TC%, 2)] as the horizontal coordinate and the cycle number (Ct value) as the vertical coordinate to obtain the calculation formula to achieve quantitative analysis of the residual tumor cells in the sample. After testing, the detection limit of this solution can reach 5 / 100,000, which greatly improves the detection sensitivity compared with flow cytometry, immunohistochemistry, in situ hybridization and other methods.

[0029] 2. The technical solution of the present application realizes the low-cost and high-sensitivity detection of extremely low proportions of residual non-small cell lung cancer in TIL products, ensuring the safety of TIL products. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Example 2 PCR amplification results.

[0031] Figure 2 Example 3 qPCR amplification curve.

[0032] Figure 3 Example 3 qPCR melting curve.

[0033] Figure 4 Example 4 qPCR amplification curve.

[0034] Figure 5 Example 4 Linear regression equation.

[0035] Figure 6 Example 5TC proportional dilution method.

[0036] Figure 7 Example 5 qPCR amplification curve.

[0037] Figure 8 Example 5 Linear regression equation.

[0038] Fig. 9 Amplification curve of quality control samples in Example 7. DETAILED DESCRIPTION

[0039] The following will combine the embodiments and drawings to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the embodiments described are only preferred embodiments, not all embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application;

[0040] Implementation Case 1: Design and Synthesis of Primers

[0041] The gene sequence of human CK7 mRNA (GenBank accession#: NM_005556.4) was obtained from Genebank, and primer design software such as Primer5, Oligo7, and DNAMAN were used to design and synthesize specific primers that only amplify CK7. The primer information is described in Table 1 below:

[0042] Table 1

[0043]

[0044]

[0045] Implementation case 2: CK7 expression specificity detection (PCR method)

[0046] Sample source: TC cDNA, TIL cDNA

[0047] Primer sequences:

[0048] Forward primer: 5′-TCCGCGAGGTCACCATTAAC-3′;

[0049] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0050] PCR Kit: HSDNA Polymerase (Brand: TAKARA, Product No.: R010A)

[0051] The PCR reaction system is shown in Table 2 below:

[0052] Table 2

[0053] Reagent volume FinalConc. 5xPrimerSTARReactionBuffer 10μL 1x dNTPs (2.5mM Each) 4μL 200μM Forward Primer (10 μM) 1μL 200nM Reverse Primer (10 μM) 1μL 200nM cDNATemplate 2μL - PrimerSTARPolymerase 0.5μL -

[0054] The PCR reaction program is shown in Table 3 below:

[0055] Table 3

[0056]

[0057] The experimental results are detailed in the attached Figure 1 , from the attached Figure 1 It can be seen that the PCR amplification results showed that CK7 was expressed in lung cancer tumor cells but not in TILs.

[0058] Implementation case 3: CK7 expression specificity detection (qPCR method)

[0059] Sample source: TC cDNA, TIL cDNA

[0060] Primer sequences:

[0061] Forward primer: 5′-TCCGCGAGGTCACCATTAAC-3′;

[0062] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0063] qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version (brand: TIANGEN, product number: FP205);

[0064] The specific qPCR reaction system is shown in Table 4 below:

[0065] Table 4

[0066]

[0067]

[0068] The qPCR reaction procedure is shown in Table 5 below:

[0069] Table 5

[0070]

[0071] The experimental results are shown in Table 6 below:

[0072] Table 6

[0073] Number of cycles TC-Repeat 1 15.649 TC-Repeat 2 15.539 TC-Repeat 3 15.504 TIL-Replicate 1 Undetermined TIL-replicate 2 34.692 TIL-replicate 3 Undetermined

[0074] The experimental results showed that CK7 expression could be stably detected in tumor cells using the qPCR method, but could not be detected in TILs;

[0075] qPCR amplification curve and melting curve for details please refer to the attached Figure 2-3 shown.

[0076] Implementation Case 4: qPCR Dilution Linearity Detection

[0077] Sample source: TC cDNA

[0078] Primer sequences:

[0079] Forward primer: 5′-TCCGCGAGGTCACCATTAAC-3′;

[0080] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0081] qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version (brand: TIANGEN, item number: FP205)

[0082] qPCR reaction procedure and reaction system: same as implementation case 3;

[0083] The specific concentration gradient dilution of TC cDNA is shown in Table 7 below:

[0084] Table 7

[0085] Group cDNA dilution factor Sample volume Sample 1 0 2μL Sample 2 0 1μL Sample 3 5 1μL Sample 4 25 1μL Sample 5 125 1μL Sample 6 625 1μL Sample 7 3125 1μL Sample 8 15625 1μL

[0086] The experimental results are shown in Table 8 below:

[0087] Table 8

[0088]

[0089]

[0090] The qPCR amplification curve of Example 4 is shown in Figure 4 The linear regression equation is shown in Figure 5 shown.

[0091] Implementation case 5: qPCR method to detect the lower limit of tumor cell residues:

[0092] Sample source: TC cells, TIL cells;

[0093] Primer sequences:

[0094] Forward primer: 5′-TCCGCGAGGTCACCATTAAC-3′;

[0095] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0096] qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version (brand: TIANGEN, item number: FP205)

[0097] qPCR reaction procedure and system: same as implementation case 3;

[0098] The cell density of TC cells and TIL cells was adjusted to 2.00E+06 / mL, and then Figure 6 The TC ratio was diluted in equal proportions.

[0099] RNA was extracted from the mixed cells, and 1ug of RNA was taken from each cell for reverse transcription into cDNA. The cDNA stock solution was diluted 10 times and used as a qPCR template for qPCR quantitative analysis. The qPCR amplification curve is shown in the attached Figure 7 .

[0100] Experimental results and: Using the qPCR method, CK7 expression can be stably detected when the TC ratio is more than 5 / 100,000; when the TC ratio is less than 5 / 100,000, non-specific amplification will occur, so the detection limit of this method is 5 / 100,000; qPCR amplification curve and linear regression equation refer to the attached Figure 7-8 shown.

[0101] Case study 6: Developing a standard curve for qPCR detection of residual tumor cells

[0102] Sample source: TC cells, TIL cells

[0103] Primer sequences:

[0104] Forward primer: 5′-TCCGCGAGGTCACCATTAAC-3′;

[0105] Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′;

[0106] qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version (brand: TIANGEN, product number: FP205);

[0107] After repeated tests, it was found that the lower limit of detection of tumor cell residues by this method is 5 / 100,000. When the tumor cell ratio is 5 / 100,000, the presence of tumor cells can be stably detected. The standard curve is set with 100% as the upper limit of detection and 0.005% as the lower limit of detection. For details, refer to Table 9 below:

[0108] Table 9

[0109]

[0110]

[0111] Inter-batch stability of the standard curve: The standard curve was drawn with the negative value of the logarithmic value of the TC% concentration as the abscissa and the cycle number Ct value as the ordinate, as shown in Table 10 below:

[0112] Table 10

[0113]

[0114] After many experiments, it was found that the qPCR method can stably detect 5 / 100,000 tumor cell residues, and the inter-batch accuracy of standard sample detection ranges from -28.66% to 50.41%, both between -75% and 150%. See Table 11 below for specific data:

[0115] Table 11

[0116]

[0117]

[0118] Implementation case 7: qPCR tumor cell residual method precision and accuracy detection:

[0119] PBMC cells and TC cells were mixed to prepare the lower limit of quantification (LLOQ, Lower limit of quantification) sample: 5 / 100,000 tumor cells, upper limit of quantification (ULOQ, Upper limit of quantification) sample: 100% tumor cells, high concentration quality control (HQC, High Quality control) sample: 25% tumor cells, medium concentration quality control (MQC, Middle Quality control) sample: 2.5% tumor cells, low concentration quality control (LQC, Low Quality control) sample: 0.25% tumor cells. The primers in Implementation Case 1 were used for qPCR reaction. The precision and accuracy of samples of different concentrations within and between batches were investigated. The guidelines for validation of quantitative analysis methods for biological samples in the standard reference pharmacopoeia (14-16) were accepted, as shown in Table 12 below:

[0120] Table 12

[0121]

[0122]

[0123] Note: Accuracy is calculated as RE% using the formula: RE% = (C measured - C theoretical or C0) / C theoretical or C0 × 100%

[0124] Precision is CV%, calculation formula: CV% = standard deviation / average value × 100%

[0125] The results showed that the CV% values ​​of LLOQ and LQC were ≤70%, while the CV% values ​​of MQC, HQC and ULOQ were ≤60%; the RE% values ​​of all test items were between -75% and 150%. The specific data are shown in Table 13 below:

[0126] Table 13

[0127]

[0128] For details on the amplification curves of quality control samples, please refer to the attached Fig. 9 shown.

[0129] Implementation Case 8: Detection of residual tumor cells in three batches of TIL products

[0130] Lung cancer cells and PBMC cells were used to prepare standard curves according to the method of "Implementation Case 6", and the linear regression equation was calculated. A549 cDNA was set as the positive control (Positive Control) and PBMC cDNA was set as the negative control (Negative Control). The residual tumor cells in three batches of TIL products (batch numbers: 20221123, 20230217, and 20230322) were detected by RT-qPCR. For details, refer to Table 14 below:

[0131] Table 14

[0132]

[0133]

[0134] The test results showed that the residual tumor cells in the three batches of TIL products, 20221123, 20230217 and 20230322, were all below the detection limit (5 parts per 100,000).

[0135] Through the above embodiments and test results, it can be seen that the present application has determined through reasonable screening and verification that CK7 protein is expressed in almost all lung adenocarcinoma cells but not expressed in immune cells, and is a very ideal TAA; by reasonably designing primers, specific amplification of the CK7 gene in vitro is achieved, and the reverse transcription quantitative PCR method is used to perform linear regression curve analysis with the inverse of the logarithm of the tumor cell (TumorCell, TC) ratio [-log(TC%, 2)] as the horizontal coordinate and the cycle number (Ct value) as the vertical coordinate to obtain a calculation formula to achieve quantitative analysis of the residual tumor cells in the sample; after testing, the lower limit of the detection of residual non-small cell lung cancer cells by this method can reach 5 / 100,000, which is much more sensitive than flow cytometry, immunohistochemistry, in situ hybridization and other methods; and the detection process has high accuracy and strong repeatability.

Claims

1. A method for detecting residual tumor in TIL products with high sensitivity, characterized in that: This detection method is used to detect the residual amount of tumor cells in tumor infiltrating lymphocytes.

2. The method for detecting residual tumor in TIL products with high sensitivity according to claim 1, characterized in that: This detection method is used to detect the residual amount of lung cancer tumor cells in tumor infiltrating lymphocytes.

3. The method for detecting residual tumor in TIL products with high sensitivity according to any one of claims 1 to 2, characterized in that: The detection method uses qPCR amplification.

4. The method for detecting residual tumor in TIL products with high sensitivity according to claim 3, characterized in that: The reaction system of the qPCR amplification method uses specific primers, and the sequences of the specific primers are as follows: Forward primer: 5'-TCCGCGAGGTCACCATTAAC-3', Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′.

5. The method for detecting residual tumor in TIL products with high sensitivity according to claim 4, characterized in that: The specific primers are used to amplify the CK7 gene.

6. The method for detecting residual tumor in TIL products with high sensitivity according to claim 4, characterized in that: The detection limit of this detection method reaches 5 parts per 100,000.

7. The method for detecting residual tumor in TIL products with high sensitivity according to claim 2, characterized in that: In the qPCR amplification reaction system, the concentration of the forward primer is 10 μM, and the concentration of the reverse primer is 10 μM.

8. The method for detecting residual tumor in TIL products with high sensitivity according to claim 4, characterized in that: The detection process of the method also uses quality control samples. The quality control samples are prepared by mixing PBMC cells and TC cells to prepare the lower limit sample of quantitative analysis: 5 / 100,000 tumor cells; the upper limit sample of quantitative analysis: 100% tumor cells; high concentration quality control sample: 25% tumor cells; medium concentration quality control sample: 2.5% tumor cells; low concentration quality control sample: 0.25% tumor cells.

9. The method for detecting residual tumor in TIL products with high sensitivity according to claim 4, characterized in that: The qPCR amplification method is as follows: Sample source: TC cDNA, TIL cDNA; Primer sequences: Forward primer: 5'-TCCGCGAGGTCACCATTAAC-3', Reverse primer: 5′-GCTCTGTCAACTCCGTCTCAT-3′; qPCR kit: SuperReal fluorescence quantitative premix reagent enhanced version; The reaction system for qPCR is: The qPCR reaction procedure is:

10. Use of the high-sensitivity tumor residual detection method in a TIL product according to claim 9 in a kit, characterized in that: The kit contains reagents: 2x SuperReal PreMix Plus, Forward Primer (10μM), Reverse Primer (10μM), 50×ROX Reference Dye, RNase-free ddH2O.

Citation Information

Cited By

  • Method for detecting cell gene editing efficiency through CRISPR / Cas9 in-vitro shearing method and application

    CN121674539A

  • Method for detecting tumor residuals in cellular therapy product

    WO2025256538A1